Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
FOXO4-DRI vs MOTS-c
An educational, source-based comparison of FOXO4-DRI and MOTS-c — how each peptide works, what it's researched for, and what to know before going deeper.
A D-retro-inverso peptide that disrupts the FOXO4-p53 interaction inside senescent cells, selectively triggering their apoptosis while sparing healthy cells in preclinical models.
- Senescent cell clearance
- Tissue function in aged mice
- Fibrotic disease models
- • No human trials; safety and pharmacokinetics in humans unknown.
- • Not FDA-approved.
A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Research suggests it activates AMPK, enhances insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress — positioning it as a candidate mitochondrial-nuclear signaling peptide.
- Insulin sensitivity
- Exercise capacity and mitochondrial biogenesis
- Age-related metabolic decline
- Obesity models
- • Early-stage research; no approved human therapeutic use.
- • Long-term effects unknown.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| FOXO4-DRI | Targeted apoptosis of senescent cells restores tissue homeostasis | Cell | 2017 | Foundational paper establishing FOXO4-DRI as a selective senolytic in mice. |
| MOTS-c | The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis | Cell Metabolism | 2015 | Foundational paper establishing AMPK-dependent metabolic effects. |
| MOTS-c | MOTS-c levels decline with age | Aging | 2018 | Circulating MOTS-c associated with age-related metabolic phenotypes. |
Side-effect & safety grid
- No human trials; safety and pharmacokinetics in humans unknown.
- Not FDA-approved.
- Early-stage research; no approved human therapeutic use.
- Long-term effects unknown.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
FOXO4-DRI vs MOTS-c — Key differences
- Class: FOXO4-DRI is classified as Longevity · Senolytic, while MOTS-c is Mitochondrial · Metabolic.
- Primary research focus: FOXO4-DRI — senescent cell clearance; MOTS-c — insulin sensitivity.
- Tag: Longevity · Senolytic vs Longevity.